Chang Limited is in the development phase of creating a new form of medicine. In the past, the company has always capitalized development costs as long as the criteria under IFRS and ASPE were met. Chang would now like to expense these costs. Discuss the options for treating this change (if any) under
(a) ASPE and
(b) IFRS, noting what type of change it is (a change in accounting policy, a change in estimate, or correction of an error).